Accretion Pharmaceuticals is a contract manufacturer that makes the pills, syrups and creams other pharma companies sell under their own names - but it also sells its own brands directly, giving it two ways to grow from the same factory. Founded in 2012 by four pharmacists in Ahmedabad and listed in May 2025, the company was built on a simple idea: own a single, internationally certified plant that can produce a wide enough range of medicines to serve both Indian distributors and importers across Africa, Southeast Asia and Latin America. Everything it does flows from that one facility and a recurring approach - get the plant approved by foreign regulators so customers can skip the two-year wait, then keep those customers by being able to make almost anything they need.
Business segments
A single manufacturing engine serving three revenue channels - contract manufacturing for other pharma companies, direct sales of its own brands, and loan licensing - all from one multi-certified plant in Gujarat.
1. Contract manufacturing: the factory behind other people's brands
The company makes finished medicines for other pharmaceutical firms, who then sell them under their own labels - it is paid for production, not for the brand.
- One plant, five dosage forms - the factory in Sanand, Gujarat, can produce tablets, capsules, oral liquids, oral powders and external preparations (ointments, creams, gels and medicated shampoos), with a total installed capacity of 1,635 million units per year. That breadth means a single client can source most of its portfolio from one supplier.
- Regulatory approvals are the product - the plant holds WHO-cGMP certification and country-specific approvals from Cambodia, Rwanda, Nigeria and Malawi, which let the company export directly to those markets without the client first having to register the factory themselves, a process that normally takes one to two years. The company is authorised to manufacture 1,198 products offshore, with over 100 more under registration.
- Broad, not deep - rather than specialising in one therapy, the company makes products across 20 therapeutic areas, from antibiotics and anti-diabetics to vitamins and cardiac drugs. Management says this is deliberate: the goal is to handle a customer's entire product mix, not just one line.
- Small clients, recurring orders - the customer base is described as "very small distributors or other companies," with 165 active clients and the top 10 accounting for roughly 64% of revenue. The model runs on both one-time contracts and repeat orders.
2. Direct sales: selling its own brands at home and abroad
The company also sells generic and branded formulations under its own name, reaching over 16 Indian states and more than 30 countries through a mix of direct exports and merchant exporters.
- Export-led, but shifting channels - international sales go out through two routes: direct exports to countries where the plant is already registered, and indirect exports through more than 70 merchant exporters who take the product to markets including Congo, Libya, Angola, Botswana, Venezuela and Cambodia. The stated strategy is to move from merchant exports toward higher-margin direct exports by building more country and product registrations.
- Domestic reach without a sales force - in India, the company sells directly to distributors rather than through medical representatives, keeping the cost structure lean. Its domestic footprint covers more than 16 states, from Gujarat and Maharashtra to Tamil Nadu, Delhi and Lakshadweep.
- The plant registration moat - entering a new country requires the local regulator to audit and approve the factory first, a barrier that locks out unapproved competitors. Because Accretion's plant registration process is underway in several African and Southeast Asian nations, it can offer importers a faster route to market once completed. The company is now working on market access in the Philippines, Ghana and Sierra Leone.
3. Loan licensing: renting out the manufacturing licence
Under loan licensing arrangements, the company allows other firms to use its manufacturing licence to produce medicines at its facility - a capital-light revenue stream that fills capacity.
- Licence as a service - a loan licence lets another company manufacture drugs using Accretion's factory and regulatory licences, including its Form 25 and Form 28 approvals under the Drugs and Cosmetics Rules. The licensee gets access to a certified plant without building one; Accretion gets paid for the use of its facility and compliance infrastructure.
- Part of the integrated model - loan licensing sits alongside contract manufacturing and direct sales as the third revenue channel, giving the company flexibility to monetise its single plant in different ways depending on demand.
Group structure and partners
The company has no subsidiaries or joint ventures - it is a single-entity business run by its four founding promoters, each a pharmacist by training.
- As of March 2025, the company had no subsidiaries, joint ventures or associate companies. Before the May 2025 IPO, it was wholly owned by the promoter group; afterward, a substantial portion of shares is held by public investors.